ArticlePharmaceutical research2018

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

Shima Gholizadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.